Sort
85,873 grants matching “alzheimers”
DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
$5,026,638Natalia S Rost · Massachusetts General Hospital · U19 · FY2019 · NS
Biomarkers of Cognitive Decline Among Normal Individuals: The Biocard Cohort
$5,018,550Marilyn S Albert · Johns Hopkins University · U19 · FY2023 · AG
Clinical & biological signatures of post-traumatic neurodegeneration: Leveraging the TBI Model Systems of Care to accelerate in vivo diagnosis of the late effects of TBI (LETBI)
$5,005,696Kristen Dams-O'Connor · Icahn School Of Medicine At Mount Sinai · RF1 · FY2022 · NS
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
$5,001,194Paul S. Aisen · University Of Southern California · R01 · FY2017 · AG
The IU/JAX Alzheimer's Disease Precision Models Center
$5,000,000Bruce T Lamb · Indiana University Indianapolis · U54 · FY2018 · AG
The IU/JAX Alzheimer's Disease Precision Models Center
$5,000,000Bruce T Lamb · Indiana University Indianapolis · U54 · FY2019 · AG
The IU/JAX Alzheimer's Disease Precision Models Center
$5,000,000Bruce T Lamb · Indiana University Indianapolis · U54 · FY2016 · AG
The IU/JAX Alzheimer's Disease Precision Models Center
$5,000,000Bruce T Lamb · Indiana University Indianapolis · U54 · FY2021 · AG
The IU/JAX Alzheimer's Disease Precision Models Center
$5,000,000Bruce T Lamb · Indiana University Indianapolis · U54 · FY2017 · AG
Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies
$4,998,007Thomas T Perls · Boston University Medical Campus · UH3 · FY2022 · AG
First stage single-cell brain resource for Alzheimer's disease and related dementias
$4,993,814Andrew Singleton · National Institute On Aging · ZIA · FY2022 · AG
PET Radiopharmaceutical Sciences
$4,988,594Victor W Pike · National Institute Of Mental Health · ZIA · FY2022 · MH
Core A: Administrative and Enrollment Core
$4,982,085Li-San Wang · University Of Pennsylvania · U19 · FY2024 · AG
Biomarkers of Cognitive Decline Among Normal Individuals: The Biocard Cohort
$4,979,715Marilyn S Albert · Johns Hopkins University · U19 · FY2019 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
$4,967,947Paul S. Aisen · University Of Southern California · R01 · FY2018 · AG
APOE in the Predisposition to, Protection from and Prevention of Alzheimer's Disease
$4,963,475Eric M Reiman · Banner Health · R01 · FY2024 · AG
NIA Information Resource Center Clearinghouse and The Alzheimer's Disease Education and Referral Center (ADEAR)
$4,958,752Johnson, Bassin And Shaw, Inc. · N02 · FY2017 · DA
Educational and Early Life Predictors of Mild Cognitive Impairment: New Evidence about Mediators and Moderators from High School & Beyond
$4,952,054John Robert Warren · University Of Minnesota · R01 · FY2022 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
$4,951,060Richard C. Mohs · Agenebio, Inc. · R01 · FY2018 · AG
Dissecting neuron-microglia-astrocyte interaction in AD pathogenesis
$4,950,325Junmin Peng · St. Jude Children'S Research Hospital · RF1 · FY2020 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
$4,948,571Richard C. Mohs · Agenebio, Inc. · R01 · FY2019 · AG
Gateway Exposome Coordinating Center (GECC) For AD/ADRD Research
$4,943,526Jinkook Lee · University Of Southern California · U24 · FY2024 · AG
Gateway Exposome Coordinating Center (GECC) For AD/ADRD Research
$4,943,481Jinkook Lee · University Of Southern California · U24 · FY2025 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
$4,942,354Richard C. Mohs · Agenebio, Inc. · R01 · FY2020 · AG
Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies
$4,939,661Thomas T Perls · Boston University Medical Campus · UH3 · FY2023 · AG